TELA Bio, Inc. (TELA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TELA SEC filings page.
TELA Bio, Inc. (TELA) reported $79.9M in revenue over the twelve months to Jun 30, 2026, up 6.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but operating losses remain and financing supports a thinner equity base rather than self-funded growth.
Revenue reached$80.3M in FY2025 after$69.3M in FY2024, while gross margin stayed near67.0% ; the combination points to added sales improving fixed-cost absorption without changing the underlying margin structure. Operating loss remained$33.8M , showing that growth has not yet translated into operating profitability.
Cash conversion remains incomplete: operating cash flow of
The balance sheet became materially more leveraged: debt-to-equity moved from 1.4x in FY2024 to 8.8x in FY2025 as equity contracted relative to liabilities. The provided liquidity comparison was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of TELA Bio, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
TELA Bio, Inc. held $50.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $28.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and TELA Bio, Inc. scores 47/100 among other emerging companies.
TELA Bio, Inc. had 45M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and TELA Bio, Inc. scores 25/100 among other emerging companies.
TELA Bio, Inc. spent $9.2M on research and development in fiscal year 2025, which was 8.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and TELA Bio, Inc. scores 32/100 among other emerging companies.
TELA Bio, Inc. reported revenue of $80.3M in fiscal year 2025, against $69.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and TELA Bio, Inc. scores 62/100 among other emerging companies.
TELA Bio, Inc.'s operations used $28.2M of cash in fiscal year 2025, against $41.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and TELA Bio, Inc. scores 62/100 among other emerging companies.
TELA Bio, Inc.'s cash, cash equivalents and investments came to $50.8M at the end of fiscal year 2025, against $75.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and TELA Bio, Inc. scores 50/100 among other emerging companies.
TELA Bio, Inc. scores -5.97, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($50.1M) relative to total liabilities ($75.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
TELA Bio, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
TELA Bio, Inc. reported a net loss of $38.8M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
TELA Bio, Inc. reported an operating loss of $33.8M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
TELA Bio, Inc. generated $19.3M in revenue in Q2 2026. This represents a decrease of 4.5% from the same quarter a year earlier. Against the prior quarter it is up 1.2%.
TELA Bio, Inc.'s EBITDA was -$9.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.3% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
TELA Bio, Inc. reported -$11.3M in net income in Q2 2026. This represents a decrease of 13.5% from the same quarter a year earlier. Against the prior quarter it is up 8.2%.
TELA Bio, Inc. earned -$0.20 per diluted share (EPS) in Q2 2026. This represents an increase of 9.1% from the same quarter a year earlier. Against the prior quarter it is up 4.8%.
Cash & Balance Sheet
TELA Bio, Inc. recorded an outflow of $9.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 17.7% from the same quarter a year earlier. Against the prior quarter it is up 16.4%.
TELA Bio, Inc. held $30.4M in cash against $56.1M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
TELA Bio, Inc.'s gross margin was 72.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.6 percentage points.
TELA Bio, Inc.'s operating margin was -48.1% in Q2 2026, reflecting core business profitability. This is down 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.1 percentage points.
TELA Bio, Inc.'s net profit margin was -58.4% in Q2 2026, showing the share of revenue converted to profit. This is down 9.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.0 percentage points.
Not reported for Q2 2026.
Capital Allocation
TELA Bio, Inc. invested $2.7M in research and development in Q2 2026. This represents an increase of 23.6% from the same quarter a year earlier. Against the prior quarter it is up 16.2%.
TELA Bio, Inc. invested $59K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 48.2% from the same quarter a year earlier. Against the prior quarter it is down 50.4%.
Not reported for Q2 2026.
TELA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.3M-4.5% | $19.1M+2.9% | $20.9M+18.2% | $20.7M+9.1% | $20.2M+25.5% | $18.5M+11.5% | $17.6M+3.8% | $19.0M+25.9% |
| Cost of Revenue | $5.3M-12.4% | $6.4M+9.0% | $7.0M+10.8% | $6.6M+10.3% | $6.0M+21.8% | $5.9M+14.3% | $6.3M+20.0% | $6.0M+31.4% |
| Gross Profit | $13.9M-1.1% | $12.5M+0.1% | $13.8M+22.6% | $14.0M+8.6% | $14.1M+27.4% | $12.5M+10.4% | $11.2M-3.5% | $12.9M+23.8% |
| R&D Expenses | $2.7M+23.6% | $2.3M-7.8% | $2.1M+4.9% | $2.3M+13.5% | $2.2M-5.2% | $2.5M+6.1% | $2.0M-24.4% | $2.1M-12.7% |
| SG&A Expenses | $4.1M-1.6% | $4.2M+8.6% | $3.8M+5.4% | $3.9M+7.2% | $4.1M+13.9% | $3.8M+0.2% | $3.6M-11.4% | $3.7M-1.2% |
| Operating Income | -$9.3M-2.2% | -$10.5M-0.5% | -$6.6M+20.4% | -$7.6M+19.3% | -$9.1M+21.5% | -$10.5M-117.0% | -$8.4M+32.0% | -$9.4M+8.0% |
| EBITDA | -$9.1M-2.3% | -$10.4M-0.6% | -$6.5M+20.3% | -$7.4M+19.5% | -$8.9M+22.0% | -$10.3M-119.8% | -$8.2M+33.0% | -$9.2M+8.6% |
| Interest Expense | $2.1M+74.7% | $2.1M+68.4% | $1.6M+27.6% | $1.2M-10.6% | $1.2M-10.7% | $1.2M-8.5% | $1.3M-4.6% | $1.3M+0.7% |
| Income Tax | $60K+81.8% | $60K+15.4% | N/A | N/A | $33K | $52K | N/A | N/A |
| Net Income | -$11.3M-13.5% | -$12.3M-9.0% | -$9.0M+1.7% | -$8.6M+17.1% | -$9.9M+21.2% | -$11.3M-99.0% | -$9.2M+29.1% | -$10.4M+5.3% |
| EPS (Basic) | -$0.20+9.1% | -$0.21+16.0% | -$0.170.0% | -$0.19+54.8% | -$0.22+56.9% | -$0.25-8.7% | -$0.17+67.9% | -$0.42+6.7% |
| EPS (Diluted) | -$0.20+9.1% | -$0.21+16.0% | -$0.170.0% | -$0.19 | -$0.22 | -$0.25 | -$0.17 | -$0.42+6.7% |
| Diluted Shares (Avg) | 57M+26.6% | 57M+26.5% | N/A | 45M | 45M | 45M | N/A | 25M+0.9% |
TELA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.7M-11.5% | $69.9M-9.5% | $81.4M-6.0% | $61.6M+16.2% | $67.5M+12.2% | $77.3M+7.5% | $86.6M+10.9% | $53.0M-39.3% |
| Current Assets | $54.5M-10.3% | $64.3M-7.8% | $75.6M-3.2% | $56.0M+27.0% | $60.7M+18.9% | $69.7M+11.4% | $78.1M+8.8% | $44.1M-46.3% |
| Cash & Equivalents | $30.4M-13.0% | $39.5M-7.7% | $50.8M-3.5% | $29.7M+71.7% | $35.0M+32.0% | $42.8M+15.3% | $52.7M+12.7% | $17.3M-70.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $11.1M-2.7% | $12.2M-9.8% | $11.0M-13.8% | $11.6M-15.0% | $11.4M-15.0% | $13.5M-0.5% | $12.8M-2.9% | $13.6M-5.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $75.6M+29.6% | $75.1M+27.0% | $75.1M+29.2% | $60.0M+1.3% | $58.4M+1.8% | $59.1M+2.9% | $58.1M-1.8% | $59.3M+4.4% |
| Current Liabilities | $18.2M-4.4% | $17.8M+7.8% | $18.0M+15.2% | $17.0M+0.7% | $19.1M+27.2% | $16.5M+8.9% | $15.6M-8.1% | $16.9M+9.9% |
| Non-Current Liabilities | $57.4M+46.1% | $57.3M+34.4% | $57.1M+34.4% | $43.1M+1.5% | $39.3M-7.2% | $42.6M+0.8% | $42.5M+0.7% | $42.4M+2.4% |
| Long-Term Debt | $56.1M+47.4% | $55.9M+35.4% | $55.7M+35.3% | $41.5M+1.3% | $38.1M-6.8% | $41.3M+1.5% | $41.1M+1.5% | $41.0M+1.5% |
| Total Equity | -$15.9M-272.8% | -$5.2M-128.7% | $6.3M-77.8% | $1.6M+124.8% | $9.2M+220.0% | $18.1M+26.0% | $28.5M+50.7% | -$6.3M-120.5% |
| Retained Earnings | -$421.1M-10.8% | -$409.8M-10.8% | -$397.6M-10.8% | -$388.5M-11.2% | -$379.9M-12.0% | -$370.0M-13.3% | -$358.7M-11.8% | -$349.5M-13.5% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
TELA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.4M-18.7% | -$11.2M-14.9% | -$4.9M+35.3% | -$5.7M+36.3% | -$7.9M+26.1% | -$9.7M+32.4% | -$7.5M+31.9% | -$9.0M-28.9% |
| Depreciation & Amortization | $171K-2.3% | $169K-1.7% | $130K-24.0% | $153K-8.9% | $175K+13.6% | $172K+23.7% | $171K+159.1% | $168K+36.6% |
| Stock-Based Compensation | $613K-37.8% | $816K-21.8% | N/A | $955K-11.7% | $985K-9.6% | $1.0M-5.3% | N/A | $1.1M-21.0% |
| Capital Expenditures | $59K-48.2% | $119K+271.9% | $91K-65.5% | $211K+73.0% | $114K-61.9% | $32K-89.5% | $264K+28.8% | $122K-9.0% |
| Free Cash Flow | -$9.4M-17.7% | -$11.3M-15.7% | -$5.0M+36.4% | -$5.9M+34.9% | -$8.0M+27.1% | -$9.8M+33.6% | -$7.8M+30.7% | -$9.1M-28.2% |
| Investing Cash Flow | $239K+17.2% | $190K+37.7% | $192K+201.1% | $312K+355.7% | $204K+204.5% | $138K-97.1% | -$190K+1.6% | -$122K+9.0% |
| Financing Cash Flow | -$15K-400.0% | -$298K-156.9% | $25.8M-39.8% | $24K-75.5% | -$3K+40.0% | -$116K-307.1% | $42.9M+194936.4% | $98K+38.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TELA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3%+2.4pp | 65.7%-1.9pp | 65.9%+2.3pp | 67.5%-0.3pp | 69.8%+1.0pp | 67.6%-0.7pp | 63.6%-4.8pp | 67.8%-1.2pp |
| Operating Margin | -48.1%-3.2pp | -55.2%+1.3pp | -31.9%+15.5pp | -36.5%+12.9pp | -45.0%+26.9pp | -56.5%-27.5pp | -47.3%+24.9pp | -49.4%+18.2pp |
| Net Margin | -58.4%-9.2pp | -64.4%-3.6pp | -43.2%+8.8pp | -41.6%+13.1pp | -49.1%+29.2pp | -60.8%-26.7pp | -51.9%+24.1pp | -54.7%+18.1pp |
| Return on Equity | N/A | N/A | -142.7%-110.5pp | -552.5% | -108.0%+331.0pp | -62.2%-22.8pp | -32.2%+36.2pp | N/A |
| Return on Assets | -18.9%-4.2pp | -17.6%-3.0pp | -11.1%-0.5pp | -14.0%+5.6pp | -14.7%+6.2pp | -14.6%-6.7pp | -10.6%+6.0pp | -19.6%-7.0pp |
| Current Ratio | 2.99-0.2x | 3.61-0.6x | 4.20-0.8x | 3.30+0.7x | 3.19-0.2x | 4.22+0.1x | 5.01+0.8x | 2.62-2.7x |
| Debt-to-Equity | N/A | N/A | 8.82+7.4x | 26.65 | 4.14-10.1x | 2.28-0.5x | 1.45-0.7x | N/A |
| Asset Turnover | 0.320.0x | 0.270.0x | 0.26+0.1x | 0.340.0x | 0.300.0x | 0.240.0x | 0.200.0x | 0.36+0.2x |
| FCF Margin | -48.9%-9.2pp | -59.2%-6.6pp | -23.8%+20.4pp | -28.7%+19.4pp | -39.7%+28.6pp | -52.7%+35.8pp | -44.2%+22.1pp | -48.0%-0.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| TELA Bio, Inc. TELA | FY2025 | $80.3M | -$38.8M | -48.3% | $50.1M | 46/100 |
| Pulmonx Corporation LUNG | FY2025 | $90.5M | -$54.0M | -59.7% | $79.0M | 54/100 |
| Elutia Inc. ELUT | FY2025 | $12.3M | $53.4M | N/A | $36.6M | 26/100 |
| Xtant Medical Holdings, Inc. XTNT | FY2025 | $133.9M | $5K | 0.0% | $45.7M | 60/100 |
| Apyx Medical Corporation APYX | FY2025 | $52.8M | -$11.2M | -21.2% | $109.1M | 43/100 |
| IceCure Medical Ltd. ICCM | FY2025 | $3.4M | -$15.1M | N/A | $5.1M | 47/100 |
Where TELA Bio, Inc. Ranks
Frequently Asked Questions
What is TELA Bio, Inc.'s annual revenue?
TELA Bio, Inc. (TELA) reported $80.3M in total revenue for fiscal year 2025. This represents a 15.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is TELA Bio, Inc.'s revenue growing?
TELA Bio, Inc. (TELA) revenue grew by 15.8% year-over-year, from $69.3M to $80.3M in fiscal year 2025.
Is TELA Bio, Inc. profitable?
No, TELA Bio, Inc. (TELA) reported a net income of -$38.8M in fiscal year 2025, with a net profit margin of -48.3%.
What is TELA Bio, Inc.'s EBITDA?
TELA Bio, Inc. (TELA) had EBITDA of -$33.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does TELA Bio, Inc. have?
As of fiscal year 2025, TELA Bio, Inc. (TELA) had $50.8M in cash and equivalents against $55.7M in long-term debt.
What is TELA Bio, Inc.'s gross margin?
TELA Bio, Inc. (TELA) had a gross margin of 67.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is TELA Bio, Inc.'s operating margin?
TELA Bio, Inc. (TELA) had an operating margin of -42.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is TELA Bio, Inc.'s net profit margin?
TELA Bio, Inc. (TELA) had a net profit margin of -48.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is TELA Bio, Inc.'s return on equity (ROE)?
TELA Bio, Inc. (TELA) has a return on equity of -614.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is TELA Bio, Inc.'s free cash flow?
TELA Bio, Inc. (TELA) recorded an outflow of $28.7M in free cash flow during fiscal year 2025. This represents a 32.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TELA Bio, Inc.'s operating cash flow?
TELA Bio, Inc. (TELA) recorded an outflow of $28.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are TELA Bio, Inc.'s total assets?
TELA Bio, Inc. (TELA) had $81.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are TELA Bio, Inc.'s capital expenditures?
TELA Bio, Inc. (TELA) invested $448K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TELA Bio, Inc. spend on research and development?
TELA Bio, Inc. (TELA) invested $9.2M in research and development during fiscal year 2025.
What is TELA Bio, Inc.'s current ratio?
TELA Bio, Inc. (TELA) had a current ratio of 4.20 as of fiscal year 2025, which is generally considered healthy.
What is TELA Bio, Inc.'s debt-to-equity ratio?
TELA Bio, Inc. (TELA) had a debt-to-equity ratio of 8.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is TELA Bio, Inc.'s return on assets (ROA)?
TELA Bio, Inc. (TELA) had a return on assets of -47.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is TELA Bio, Inc.'s P/E ratio?
TELA Bio, Inc. (TELA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $50.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is TELA Bio, Inc.'s price-to-sales ratio?
TELA Bio, Inc. (TELA) trades at 0.6x sales, its market capitalization divided by revenue of $79.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $50.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does TELA Bio, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, TELA Bio, Inc. (TELA) held $50.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.2M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is TELA Bio, Inc.'s Altman Z-Score?
TELA Bio, Inc. (TELA) has an Altman Z-Score of -5.97, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is TELA Bio, Inc.'s Piotroski F-Score?
TELA Bio, Inc. (TELA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TELA Bio, Inc.'s earnings high quality?
TELA Bio, Inc. (TELA) reported a net loss of $38.8M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can TELA Bio, Inc. cover its interest payments?
TELA Bio, Inc. (TELA) reported an operating loss of $33.8M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is TELA Bio, Inc.?
TELA Bio, Inc. (TELA) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.